Cecilia Vitali1, Sumeet A Khetarpal1, Daniel J Rader2,3. 1. Perelman School of Medicine at the University of Pennsylvania, 11-162 TRC, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. 2. Perelman School of Medicine at the University of Pennsylvania, 11-162 TRC, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. rader@mail.med.upenn.edu. 3. Departments of Genetics and Medicine, Cardiovascular Institute, and Institute for Translational Medicine and Therapeutics, Perelman School of Medicine at the University of Pennsylvania, 11-125 TRC, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. rader@mail.med.upenn.edu.
Abstract
PURPOSE OF REVIEW: Elevated high-density lipoprotein cholesterol levels in the blood (HDL-C) represent one of the strongest epidemiological surrogates for protection against coronary heart disease (CHD), but recent human genetic and pharmacological intervention studies have raised controversy about the causality of this relationship. Here, we review recent discoveries from human genome studies using new analytic tools as well as relevant animal studies that have both addressed, and in some cases, fueled this controversy. RECENT FINDINGS: Methodologic developments in genotyping and sequencing, such as genome-wide association studies (GWAS), exome sequencing, and exome array genotyping, have been applied to the study of HDL-C and risk of CHD in large, multi-ethnic populations. Some of these efforts focused on population-wide variation in common variants have uncovered new polymorphisms at novel loci associated with HDL-C and, in some cases, CHD risk. Other efforts have discovered loss-of-function variants for the first time in genes previously implicated in HDL metabolism through common variant studies or animal models. These studies have allowed the genetic relationship between these pathways, HDL-C and CHD to be explored in humans for the first time through analysis tools such as Mendelian randomization. We explore these discoveries for selected key HDL-C genes CETP, LCAT, LIPG, SCARB1, and novel loci implicated from GWAS including GALNT2, KLF14, and TTC39B. Recent human genetics findings have identified new nodes regulating HDL metabolism while reshaping our current understanding of known candidate genes to HDL and CHD risk through the study of critical variants across model systems. Despite their effect on HDL-C, variants in many of the reviewed genes were found to lack any association with CHD. These data collectively indicate that HDL-C concentration, which represents a static picture of a very dynamic and heterogeneous metabolic milieu, is unlikely to be itself causally protective against CHD. In this context, human genetics represent an extremely valuable tool to further explore the biological mechanisms regulating HDL metabolism and investigate what role, if any, HDL plays in the pathogenesis of CHD.
PURPOSE OF REVIEW: Elevated high-density lipoprotein cholesterol levels in the blood (HDL-C) represent one of the strongest epidemiological surrogates for protection against coronary heart disease (CHD), but recent human genetic and pharmacological intervention studies have raised controversy about the causality of this relationship. Here, we review recent discoveries from human genome studies using new analytic tools as well as relevant animal studies that have both addressed, and in some cases, fueled this controversy. RECENT FINDINGS: Methodologic developments in genotyping and sequencing, such as genome-wide association studies (GWAS), exome sequencing, and exome array genotyping, have been applied to the study of HDL-C and risk of CHD in large, multi-ethnic populations. Some of these efforts focused on population-wide variation in common variants have uncovered new polymorphisms at novel loci associated with HDL-C and, in some cases, CHD risk. Other efforts have discovered loss-of-function variants for the first time in genes previously implicated in HDL metabolism through common variant studies or animal models. These studies have allowed the genetic relationship between these pathways, HDL-C and CHD to be explored in humans for the first time through analysis tools such as Mendelian randomization. We explore these discoveries for selected key HDL-C genes CETP, LCAT, LIPG, SCARB1, and novel loci implicated from GWAS including GALNT2, KLF14, and TTC39B. Recent human genetics findings have identified new nodes regulating HDL metabolism while reshaping our current understanding of known candidate genes to HDL and CHD risk through the study of critical variants across model systems. Despite their effect on HDL-C, variants in many of the reviewed genes were found to lack any association with CHD. These data collectively indicate that HDL-C concentration, which represents a static picture of a very dynamic and heterogeneous metabolic milieu, is unlikely to be itself causally protective against CHD. In this context, human genetics represent an extremely valuable tool to further explore the biological mechanisms regulating HDL metabolism and investigate what role, if any, HDL plays in the pathogenesis of CHD.
Authors: K Hirano; S Yamashita; N Nakajima; T Arai; T Maruyama; Y Yoshida; M Ishigami; N Sakai; K Kameda-Takemura; Y Matsuzawa Journal: Arterioscler Thromb Vasc Biol Date: 1997-06 Impact factor: 8.311
Authors: A Inazu; M L Brown; C B Hesler; L B Agellon; J Koizumi; K Takata; Y Maruhama; H Mabuchi; A R Tall Journal: N Engl J Med Date: 1990-11-01 Impact factor: 91.245
Authors: Roshni R Singaraja; Suthesh Sivapalaratnam; Kees Hovingh; Marie-Pierre Dubé; José Castro-Perez; Heidi L Collins; Steven J Adelman; Meliana Riwanto; Jasmin Manz; Brian Hubbard; Ian Tietjen; Kenny Wong; Lyndon J Mitnaul; Margaret van Heek; Linus Lin; Thomas A Roddy; Jason McEwen; Geesje Dallinge-Thie; Leonie van Vark-van der Zee; Germaine Verwoert; Michael Winther; Cornelia van Duijn; Albert Hofman; Mieke D Trip; A David Marais; Bela Asztalos; Ulf Landmesser; Eric Sijbrands; John J Kastelein; Michael R Hayden Journal: Circ Cardiovasc Genet Date: 2012-12-14
Authors: Andreas Ritsch; Gudrun Sonderegger; Gudron Sonderegger; Anton Sandhofer; Ursula Stanzl; Ursala Stanzl; Ivan Tancevski; Philipp Eller; Wilfried Schgoer; Andreas Wehinger; Thomas Mueller; Meinhard Haltmayer; Josef R Patsch; Joseph R Patsch Journal: Metabolism Date: 2007-08 Impact factor: 8.694
Authors: Sekar Kathiresan; Olle Melander; Candace Guiducci; Aarti Surti; Noël P Burtt; Mark J Rieder; Gregory M Cooper; Charlotta Roos; Benjamin F Voight; Aki S Havulinna; Björn Wahlstrand; Thomas Hedner; Dolores Corella; E Shyong Tai; Jose M Ordovas; Göran Berglund; Erkki Vartiainen; Pekka Jousilahti; Bo Hedblad; Marja-Riitta Taskinen; Christopher Newton-Cheh; Veikko Salomaa; Leena Peltonen; Leif Groop; David M Altshuler; Marju Orho-Melander Journal: Nat Genet Date: 2008-01-13 Impact factor: 38.330
Authors: Mete Civelek; Ying Wu; Calvin Pan; Chelsea K Raulerson; Arthur Ko; Aiqing He; Charles Tilford; Niyas K Saleem; Alena Stančáková; Laura J Scott; Christian Fuchsberger; Heather M Stringham; Anne U Jackson; Narisu Narisu; Peter S Chines; Kerrin S Small; Johanna Kuusisto; Brian W Parks; Päivi Pajukanta; Todd Kirchgessner; Francis S Collins; Peter S Gargalovic; Michael Boehnke; Markku Laakso; Karen L Mohlke; Aldons J Lusis Journal: Am J Hum Genet Date: 2017-03-02 Impact factor: 11.025
Authors: Benjamin F Voight; Hyun Min Kang; Jun Ding; Cameron D Palmer; Carlo Sidore; Peter S Chines; Noël P Burtt; Christian Fuchsberger; Yanming Li; Jeanette Erdmann; Timothy M Frayling; Iris M Heid; Anne U Jackson; Toby Johnson; Tuomas O Kilpeläinen; Cecilia M Lindgren; Andrew P Morris; Inga Prokopenko; Joshua C Randall; Richa Saxena; Nicole Soranzo; Elizabeth K Speliotes; Tanya M Teslovich; Eleanor Wheeler; Jared Maguire; Melissa Parkin; Simon Potter; N William Rayner; Neil Robertson; Kathleen Stirrups; Wendy Winckler; Serena Sanna; Antonella Mulas; Ramaiah Nagaraja; Francesco Cucca; Inês Barroso; Panos Deloukas; Ruth J F Loos; Sekar Kathiresan; Patricia B Munroe; Christopher Newton-Cheh; Arne Pfeufer; Nilesh J Samani; Heribert Schunkert; Joel N Hirschhorn; David Altshuler; Mark I McCarthy; Gonçalo R Abecasis; Michael Boehnke Journal: PLoS Genet Date: 2012-08-02 Impact factor: 5.917
Authors: Jaroslav A Hubacek; Dana Dlouha; Vera Adamkova; Lucie Schwarzova; Vera Lanska; Richard Ceska; Martin Satny; Michal Vrablik Journal: Mol Diagn Ther Date: 2019-08 Impact factor: 4.074
Authors: Kaylin M McMahon; Andrea E Calvert; Irina S Dementieva; Saber Hussain; John T Wilkins; C Shad Thaxton Journal: ACS Sens Date: 2020-07-14 Impact factor: 7.711
Authors: Sumeet A Khetarpal; Paul L Babb; Wei Zhao; William F Hancock-Cerutti; Christopher D Brown; Daniel J Rader; Benjamin F Voight Journal: Circ Genom Precis Med Date: 2018-07